Concepedia

Michael Sangmin Lee

MS

Statistics

Publications

10

Citations

411

H-Index

10

Active since

2016

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of North Carolina at Chapel Hill

Georgetown University

Ulsan College

Georgetown University Medical Center

Michael Sangmin Lee is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and colorectal cancer.

Publications per year

2016–2024

10

Publications

10

Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).

Stacey Stein, Michael J. Pishvaian, Michael Sangmin Lee et al. · Journal of Clinical Oncology · 2018 · 116 citations

, , +17

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancer.

Van K. Morris, Christine M. Parseghian, Michelle Escano et al. · Journal of Clinical Oncology · 2022 · 78 citations

, , +17

Phase II study of ipilimumab, nivolumab, and panitumumab in patients with <i>KRAS</i>/<i>NRAS</i>/<i>BRAF</i> wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Michael Sangmin Lee, Patrick J. Loehrer, Iman Imanirad et al. · Journal of Clinical Oncology · 2021 · 44 citations

, , +17

Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRAS<sup>G12D </sup>siRNA in patients with metastatic pancreatic cancer harboring a KRAS<sup>G12D</sup> mutation.

Rishi Surana, Valerie S. LeBleu, Brandon G. Smaglo et al. · Journal of Clinical Oncology · 2022 · 38 citations

, , +17

Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).

Chih‐Hung Hsu, Shan Lu, Alex Abbas et al. · Journal of Clinical Oncology · 2020 · 36 citations

, , +17

1–5 of 10